News | October 24, 2013

Urologists Denounce New England Journal of Medicine Article Regarding Prostate Cancer Treatment

October 24, 2014 — Large Urology Group Practice Association (LUGPA), an organization advocating for integrated and coordinated urological care, says it has reviewed the article "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer" (Mitchell, JM, New England Journal of Medicine 369:17, Oct. 24, 2013) and found it to be methodologically flawed and factually inaccurate and, as such, did not contribute to the useful interchange of ideas needed to improve healthcare or increase value.

"The Mitchell study was commissioned and funded by the American Society for Radiation Oncology (ASTRO) in an attempt to persuade lawmakers to legislate a monopoly for its members in the use of radiation therapy to treat prostate cancer — an economically-driven agenda that has been rejected by Congress, MedPAC and the GAO," said Deepak Kapoor, president of LUGPA, and chairman and CEO of Integrated Medical Professionals PLLC. "Instead of furthering our understanding of the complicated health policy issues around prostate cancer care, Dr. Mitchell's work appears to be specifically designed to produce talking points for the sponsor's political agenda, which is primarily to restore their virtual monopoly on the provision of pathology laboratory services."

The data from the study by Jean Mitchell, Ph.D., economics professor at Georgetown University, stated that less than one-third of newly diagnosed prostate cancer patients who sought treatment from an integrated urology group received intensity-modulated radiation therapy (IMRT). This figure is in line with data from academic literature that predates the development of integrated groups.[1],[2] The study did not match its control group for practice size, patient demographics or severity of disease. According to Kapoor, its selection bias is evidenced by its own bizarre results. 

For example, the group says there has been a clear national trend toward less-invasive IMRT and away from brachytherapy seen nationally across all sites of service.[3][4] Paradoxically, over the six-year study period, the use of IMRT and brachytherapy remained flat in Mitchell's control group. The fact that integrated groups' rates of active surveillance and surgery held constant further illustrates that ownership of IMRT did not affect these groups' clinical decision-making. 

"Her own data confirms that urologists with ownership of radiation oncology use the technology appropriately and responsibly,” said Kapoor. “That should be the title of Mitchell's study.”

According to Kapoor, the ASTRO study serves only one purpose, to undermine competition in the marketplace, adding that utilizing such data that demonizes groups practicing evidence-based medicine in an attempt to manipulate market share by legislative fiat is both inappropriate and offensive. Legislative changes based on such data will drive up costs as many patients will be forced to seek care in the more expensive hospital setting, and harm patient access to specialized, integrated care.

Opinions expressed in this article are those of Kapoor and David Penson, M.D., professor of urologic surgery at Vanderbilt University and director of Vanderbilt Center for Surgical Quality and Outcomes Research.


[1] Nguyen PL, Gu X, Lipsitz SR, et al.  Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer. J Clin Onc. 2010; Mar; 3: 1217 

[2] Jang TL, Bekelman JE, Liu Y, et al. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med. 2010;170(5):440-450. 

[3] Kapoor DA, Zimberg SH, Ohrin LM, et al. Utilization trends in prostate cancer therapy. J Urol. 2011 Sep;186(3):860-4. 

[4] Mahmood U, Pugh T, Frank S et al.  Declining use of brachytherapy for the treatment of prostate cancer.  Brachytherapy, in press.  Accessed at:

For more information:

Related Content

Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Overlay Init